Medicaid
Massachusetts patients could get biomarker tests covered
The proposal would require state employee plans, Medicaid and many private plans to pay for evidence-backed tests, from single-gene checks to whole-genome sequencing.
A Massachusetts bill would require coverage for biomarker testing when medical evidence supports it. For patients, that could make it easier to get the right test without paying upfront.
- Would require coverage for biomarker testing
- Applies to state employee plans, Medicaid and some private plans
- Covers everything from single-gene tests to whole-genome sequencing
- Coverage would hinge on evidence-based clinical guidance
- In Massachusetts, a lab result can decide whether a treatment is a good fit or a costly dead end
In Massachusetts, a lab result can decide whether a treatment is a good fit or a costly dead end. A proposal would require health plans to cover biomarker testing, the kind of lab analysis that looks for genetic or molecular clues doctors use to choose, adjust or monitor care.
The amendment would add a new Section 17R to Chapter 32A of the Massachusetts General Laws. It reaches state employee coverage, Medicaid and several private insurance categories, and it is written to keep insurers from treating the test as optional when medical evidence supports it.
The tests on the table
The bill defines biomarker testing broadly as the analysis of a patient’s tissue, blood or other biospecimen for biomarkers. A biomarker is a measurable characteristic that can point to normal biological processes, disease processes or how a person responds to a particular drug.
That definition includes gene mutations, characteristics of genes and protein expression. It also covers single-analyte tests, multiplex panel tests, protein expression testing and whole-exome, whole-genome and whole-transcriptome sequencing, which can stretch from narrow checks to the most advanced testing now used to match patients with targeted therapies.
The line insurers would have to follow
Coverage would turn on diagnosis, treatment, appropriate management or ongoing monitoring when the test is backed by medical and scientific evidence. The measure points to Food and Drug Administration-approved or -cleared tests, uses tied to FDA-approved drugs, FDA label warnings and precautions, Medicare coverage decisions and nationally recognized clinical practice guidelines or consensus statements.
Those consensus statements would have to come from an independent, multidisciplinary panel using transparent methods and a conflict-of-interest policy. The nationally recognized clinical practice guidelines would have to be evidence-based and produced by independent organizations or medical professional societies, with the same kind of transparency and conflict rules. In other words, the bill tries to make coverage follow the evidence, not a case-by-case insurer judgment.